RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $181.
August 15, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Sarepta Therapeutics and maintained a price target of $181.
The reiteration of an Outperform rating and a maintained price target of $181 by RBC Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100